A novel and safe SmartCap® SC101 to develop the COVID-19 mRNA vaccine STP2104 inducing potent immune responses in humans.
Saved in:
| Title: | A novel and safe SmartCap® SC101 to develop the COVID-19 mRNA vaccine STP2104 inducing potent immune responses in humans. |
|---|---|
| Authors: | Kim R; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Uhm TG; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Kim J; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Woo D; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Kim UI; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Meng X; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Yang B; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Kim S; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Kim H; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Kim J; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Yoon S; Division of Clinical Research for vaccine, Center for Vaccine Research, National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea., Lee JY; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Kim B; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Cho D; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Chang D; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Cho YH; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Choi K; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Gwak W; Division of Clinical Research for vaccine, Center for Vaccine Research, National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea., Lee HW; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Bang J; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Hellström E; Be Part Research (PTY) Ltd., Paarl, South Africa., Kim B; Division of Clinical Research for vaccine, Center for Vaccine Research, National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea., Kim K; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea., Yang JS; R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea. |
| Source: | Frontiers in immunology [Front Immunol] 2025 Jun 16; Vol. 16, pp. 1571092. Date of Electronic Publication: 2025 Jun 16 (Print Publication: 2025). |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Multicenter Study |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2025.1571092 |
